ACE and neoplasm: Angiotensin Receptor Blocker (ARB) hold anti-tumor potential by inhibiting the action of angiotensin II, as do Angiotensin-Converting Enzyme Inhibitors (ACEI), which block the generation of angiotensin II and are considered to have anti-tumor effects.